These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 18201149

  • 1. Ketolides: pharmacological profile and rational positioning in the treatment of respiratory tract infections.
    Van Bambeke F, Harms JM, Van Laethem Y, Tulkens PM.
    Expert Opin Pharmacother; 2008 Feb; 9(2):267-83. PubMed ID: 18201149
    [Abstract] [Full Text] [Related]

  • 2. The ketolides: a critical review.
    Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, Gin AS, Douthwaite S, Hoban DJ.
    Drugs; 2002 Feb; 62(12):1771-804. PubMed ID: 12149046
    [Abstract] [Full Text] [Related]

  • 3. Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections.
    Hammerschlag MR, Sharma R.
    Expert Opin Investig Drugs; 2008 Mar; 17(3):387-400. PubMed ID: 18321237
    [Abstract] [Full Text] [Related]

  • 4. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG, Hisanaga T, Nichol K, Wierzbowski A, Hoban DJ.
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [Abstract] [Full Text] [Related]

  • 5. [Multicenter study in southern South America of the in vitro activity of telithromycin in strains with defined resistance phenotypes isolated from community-acquired respiratory infections].
    Casellas JM, Visser M, Mac Dougall N, Coco B, Tomé G, Gliosca L, Grupo Colaborativo de Telitromicina del Cono Sur.
    Rev Esp Quimioter; 2001 Sep; 14(3):269-74. PubMed ID: 11753448
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of ketolides in the treatment of respiratory tract infections.
    Reinert RR.
    J Antimicrob Chemother; 2004 Jun; 53(6):918-27. PubMed ID: 15117934
    [Abstract] [Full Text] [Related]

  • 7. Will resistance to ketolides develop in Streptococcus pneumoniae?
    Leclercq R.
    J Infect; 2002 Feb; 44 Suppl A():11-6. PubMed ID: 12150490
    [Abstract] [Full Text] [Related]

  • 8. Community-acquired respiratory tract infections caused by resistant pneumococci: clinical and bacteriological efficacy of the ketolide telithromycin.
    Fogarty CM, Kohno S, Buchanan P, Aubier M, Baz M.
    J Antimicrob Chemother; 2003 Apr; 51(4):947-55. PubMed ID: 12654763
    [Abstract] [Full Text] [Related]

  • 9. From macrolides to ketolides: What is available for the treatment of outpatient respiratory tract infections?
    Carter PL.
    Postgrad Med; 2002 Sep; 112(3 Suppl):18-25. PubMed ID: 19667591
    [Abstract] [Full Text] [Related]

  • 10. The wobbly status of ketolides: where do we stand?
    Georgopapadakou NH.
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1313-9. PubMed ID: 25154307
    [Abstract] [Full Text] [Related]

  • 11. Review of macrolides and ketolides: focus on respiratory tract infections.
    Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA.
    Drugs; 2001 Oct; 61(4):443-98. PubMed ID: 11324679
    [Abstract] [Full Text] [Related]

  • 12. Telithromycin: a brief review of a new ketolide antibiotic.
    Scheinfeld N.
    J Drugs Dermatol; 2004 Oct; 3(4):409-13. PubMed ID: 15303785
    [Abstract] [Full Text] [Related]

  • 13. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J.
    Int J Clin Pract; 2003 Oct; 57(6):519-29. PubMed ID: 12918892
    [Abstract] [Full Text] [Related]

  • 14. Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia.
    Zhanel GG, Hartel E, Adam H, Zelenitsky S, Zhanel MA, Golden A, Schweizer F, Gorityala B, Lagacé-Wiens PR, Walkty AJ, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2016 Dec; 76(18):1737-1757. PubMed ID: 27909995
    [Abstract] [Full Text] [Related]

  • 15. Telithromycin: a ketolide antibiotic for treatment of respiratory tract infections.
    Lonks JR, Goldmann DA.
    Clin Infect Dis; 2005 Jun 01; 40(11):1657-64. PubMed ID: 15889365
    [Abstract] [Full Text] [Related]

  • 16. Telithromycin: the first of the ketolides.
    Shain CS, Amsden GW.
    Ann Pharmacother; 2002 Mar 01; 36(3):452-64. PubMed ID: 11895060
    [Abstract] [Full Text] [Related]

  • 17. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D.
    J Infect; 2002 Feb 01; 44 Suppl A():3-10. PubMed ID: 12150493
    [Abstract] [Full Text] [Related]

  • 18. Telithromycin: an oral ketolide for respiratory infections.
    Bearden DT, Neuhauser MM, Garey KW.
    Pharmacotherapy; 2001 Oct 01; 21(10):1204-22. PubMed ID: 11601667
    [Abstract] [Full Text] [Related]

  • 19. Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections.
    Magee TV, Ripp SL, Li B, Buzon RA, Chupak L, Dougherty TJ, Finegan SM, Girard D, Hagen AE, Falcone MJ, Farley KA, Granskog K, Hardink JR, Huband MD, Kamicker BJ, Kaneko T, Knickerbocker MJ, Liras JL, Marra A, Medina I, Nguyen TT, Noe MC, Obach RS, O'Donnell JP, Penzien JB, Reilly UD, Schafer JR, Shen Y, Stone GG, Strelevitz TJ, Sun J, Tait-Kamradt A, Vaz AD, Whipple DA, Widlicka DW, Wishka DG, Wolkowski JP, Flanagan ME.
    J Med Chem; 2009 Dec 10; 52(23):7446-57. PubMed ID: 19775168
    [Abstract] [Full Text] [Related]

  • 20. Ketolides in the treatment of respiratory infections.
    Zhanel GG, Hoban DJ.
    Expert Opin Pharmacother; 2002 Mar 10; 3(3):277-97. PubMed ID: 11866679
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.